Pediatric Primary Intramedullary Spinal Cord Glioblastoma by Lober, Robert M. et al.
Wright State University 
CORE Scholar 
Pediatrics Faculty Publications Pediatrics 
9-30-2010 
Pediatric Primary Intramedullary Spinal Cord Glioblastoma 
Robert M. Lober 
Wright State University, robert.lober@wright.edu 
Robert M. Lober 




See next page for additional authors 
Follow this and additional works at: https://corescholar.libraries.wright.edu/pediatrics 
 Part of the Pediatrics Commons 
Repository Citation 
Lober, R. M., Lober, R. M., Sharma, S., Bell, B., Free, A., Figueroa, R., Sheils, C. W., Lee, M., & Cowell, J. K. 
(2010). Pediatric Primary Intramedullary Spinal Cord Glioblastoma. Rare Tumors (3), 135-141. 
https://corescholar.libraries.wright.edu/pediatrics/428 
This Article is brought to you for free and open access by the Pediatrics at CORE Scholar. It has been accepted for 
inclusion in Pediatrics Faculty Publications by an authorized administrator of CORE Scholar. For more information, 
please contact library-corescholar@wright.edu. 
Authors 
Robert M. Lober, Robert M. Lober, Suash Sharma, Beverly Bell, Alan Free, Ramon Figueroa, Chris W. Sheils, 
Mark Lee, and John Kenneth Cowell 
This article is available at CORE Scholar: https://corescholar.libraries.wright.edu/pediatrics/428 




Robert Lober,1* Suash Sharma,1
Beverly Bell,2 Alan Free,6
Ramon Figueroa,3 Chris W. Sheils,5
Mark Lee,4** John Cowell6
Departments of 1Pathology, 2Pediatrics
(Oncology), 3Neuroradiology,
4Neurosurgery, 5Radiation Oncology, and
6MCG Cancer Center, Medical College of
Georgia, Augusta, GA, USA 
*Currently Department of Neurosurgery,
Stanford University School of Medicine,
Palo Alto, CA, USA
**Currently Department of Neurosurgery,
Dell Children’s Medical Center, Austin,
TX, USA
Abstract 
Spinal cord tumors in pediatric patients are
rare, representing less than 1% of all central
nervous system tumors. Two cases of pediatric
primary intramedullary spinal cord glioblastoma
at ages 14 and 8 years are reported. Both
patients presented with rapid onset paraparesis
and quadraparesis. Magnetic resonance imag-
ing in both showed heterogeneously enhancing
solitary mass lesions localized to lower cervical
and upper thoracic spinal cord parenchyma.
Histopathologic diagnosis was glioblastoma.
Case #1 had a small cell component (primitive
neuroectodermal tumor-like areas), higher
Ki67, and p53 labeling indices, and a relatively
stable karyotype with only minimal single copy
losses involving regions: Chr8;pter-30480019,
Chr16;pter-29754532, Chr16;56160245-
88668979, and Chr19;32848902-qter on retro-
spective comparative genomic hybridization
using formalin-fixed, paraffin-embedded sam-
ples. Case #2 had relatively bland histomorph -
ology and negligible p53 immunoreactivity. Both
underwent multimodal therapy including gross
total resection, postoperative radiation and
chemotherapy. However, there was no signifi-
cant improvement in neurological deficits, and
overall survival in both cases was 14 months.
This report highlights the broad histological
spectrum and poor overall survival despite
multi modality therapy. The finding of relatively
unique genotypic abnormalities resembling
pediatric embryonal tumors in one case may
highlight the value of genome-wide profiling in
development of effective therapy. The differ-
ences in management with intracranial and
low-grade spinal cord gliomas and current man-
agement issues are discussed.
Introduction
Spinal cord tumors are rare in children, rep-
resenting less than 1% of all central nervous
system (CNS) tumors.1-5 Within this small frac-
tion, intramedullary spinal cord (ISC) tumors
constitute about 35% of the spinal tumors
found in children6,7 compared to 5% in adults.8
Low-grade gliomas such as ependymomas and
astrocytomas account for the majority, with
only about 1-3% being high-grade gliomas.6 A
recent review of the cases of pediatric ISC-
glioblastoma (GBM) reported in the last two
decades is summarized in Table 1. Patients
were treated with multimodality therapeutic
regimens similar to their adult counterparts.
The roles of maximum safe surgical resection
and radiotherapy are well established in the
treatment of pediatric high-grade glioma in
the intracranial location, and in non-infiltra-
tive spinal cord tumors, but not in high-grade
spinal cord gliomas where recent studies dis-
courage the use of radical surgery.4 The role of
chemotherapy remains undefined.9 Based on
this limited dataset, critical underlying genom-
ic events and the determination of the optimal
therapeutic approach in this rare disease are
unknown.3 This report describes two cases of
pediatric primary ISC-GBM. Both had gross
total resection, and were treated with adjunct -
ive chemotherapy and radiation therapy as per
the Children’s Oncology Group protocol
ACNS0126 for intracranial gliomas extrapolat-
ed to high-grade spinal cord gliomas.10 Results
of comparative genomic hybridization in one
case in whom adequate tissue and call rate
was available is also provided. A review of per-
tinent literature aims to provide a comparative
and balanced perspective.
Case #1
A 14-year-old Asian–American female pre-
sented with a six-month history of lower
extremity dysesthesias, which progressed to
lower extremity weakness and gait difficulties
several days before presentation. Magnetic
resonance imaging (MRI) of the brain and
spine performed at an outside hospital
(images currently unavailable) revealed an
intramedullary enhancing mass extending
from the level of the sixth cervical (C6) to fifth
thoracic (T5) vertebra. She underwent cervical
and thoracic laminectomies with gross total
resection of the tumor. The histopathologic
diagnosis was GBM (Figure 1A-E). Post -
operatively, the patient had paraplegia and an
upper extremity strength of 1/5, which
improved to 4/5 within two weeks with steroids
and physical therapy. During rehabilitation,
she required treatment for wound infection
and dehiscence. She began the Children’s
Oncology Group protocol ACNS0126 with radi-
ation therapy and chemotherapy in the treat-
ment of high-grade glioma.10 She received 5040
cGy to her cervical and thoracic spine in 28
evenly divided fractions. On the fifth day of
radiation therapy, she began oral temozolo-
mide at 90 mg/m2/day for six weeks, followed by
a four-week rest. Maintenance therapy consist-
ed of 10 courses of 28-day cycles of oral temo-
zolomide 200 mg/m2/day for five days, followed
by 23 days of rest. During this therapy, she
reported subjective improvement in leg
strength, but remained wheelchair-bound.
MRI of the spine six months after resection
showed progression of the tumor, extending
from the level of C5 to T3. Post-radiotherapy
changes were seen throughout the spinal axis.
Nine months after resection, MRI of the spine
showed a stable lesion, with cord expansion
and myelomalacia in a similar distribution.
Whole-body PET imaging from the skull to the
thigh was negative for metastasis or lymph -
adenopathy. Fourteen months after resection,
the patient died while in hospice care.
Case #2
An eight-year-old African–American female
presented with a three-week history of neck
pain and weakness, which progressed to sig-
nificant weakness in all extremities. MRI of
the brain and spine revealed an intramedullary
enhancing mass originating from the central
portion of the spinal cord, extending from the
level of C3 to T4 with significant cord expan-
sion from C3 to T3 (Figure 2A-E). Of note, pre-
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operative cerebrospinal fluid cytology was neg-
ative for malignancy. She underwent C1 to T2
laminectomies with gross total resection of the
tumor and posterior osteoplastic arthrodesis. A
histopathologic diagnosis of GBM was made
(see Pathology section for details). Post -
operatively, she was found to have sensations
bilaterally, movement in both upper extrem -
ities, and some movement in the right foot.
She was referred to the Rehabilitation Center,
where she began treatment according to the
Children’s Oncology Group protocol
ACNS0126.10 She received fractionated radia-
tion therapy to her cervical and thoracic spine,
and oral temozolomide therapy as described
for case #1. One year after resection, MRI of
the spine demonstrated that her tumor had not
progressed. She had developed an acute angle
kyphotic deformity, most pronounced at C4 to
C5, with spinal cord compression. There was
no subsequent improvement in her neurological
deficits.
Fourteen months after resection, she present-
ed to the Emergency Department and required
intubation for respiratory failure and treatment
for severe bronchopneumonia. MRI of the brain
and spinal cord showed interval development of
edema and contrast enhancement from the
lower medulla to the level of T2, consistent with
recurrence. On her fifth hos pital day, she
became unresponsive to stimuli and had absent
corneal reflexes. The patient died the next day,
14 months after tumor resection.
Pathology 
Histological examination of the resected
masses in both cases revealed high-grade infil-
trating astrocytic neoplasms with necrosis and
microvascular proliferation. No obvious
pseudopalisading around the areas of necrosis
were seen in either case. Individual neoplastic
cells demonstrated significant nuclear pleo-
morphism, anaplasia and high mitotic activity
with scattered apoptotic bodies (Figures 1A
and B; 2F-J, respectively), including small cells
focally resembling a primitive neuroectoder-
mal tumor (PNET) but with microvascular pro-
liferation (Figure 1B). A diagnosis of GBM,
WHO grade IV, was rendered. Diffuse
immunopositivity for glial fibrillary acidic pro-
tein (GFAP) supported the diagnoses in both
cases (Figures 1C and 2K).
In case #1, there was a small cell component
and more conspicuous anaplasia as compared
to case #2. The neoplastic cells in case #1
showed a high Ki67 (MIB1) immunohisto-
chemical nuclear labeling index of up to about
30%, and a high p53 labeling index of up to
about 70% (Figure 1D and E respectively).
Immunostain for epidermal growth factor
receptor (EGFR) was negative. The ultrastruc-
tural evaluation in case #1 revealed pleomor-
phic cells with short bulbous projections and a
paucity of organelles except for mitochondria.
The nuclei were pleomorphic with conspicu-
ous heterochromatin. Glial filaments in every
cell were scattered throughout the cytosol in
discreet bundles, often associated with
Rosenthal bodies. Microtubules were found in
close-packed bundles or loose arrays in the
cytosol and cellular projections. Tumor sam-
ples from case #1, were previously analyzed
using array comparative genomic hybridiza-
tion (aCGH). These analyses revealed a rela-
tively stable karyotype with only minimal sin-
gle copy losses involving regions: Chr8;pter-
30480019, Chr16;pter-29754532, Chr16;
56160245-88668979, and Chr19;32848902-
qter.11 None of the frequent losses, gains, and
amplifications seen in adult GBM12 were iden-
tified in this sample (see Discussion).  
In case #2, the neoplastic cells were relative-
ly bland as compared to case #1. High-grade
cytological features were not apparent on
frozen sections, but diagnostic features were
seen on FFPE sections. The neoplastic cells
showed a high Ki67 (MIB1) immunohisto-
chemical nuclear labeling index of up to about
20%, but a rather low p53 labeling index of less
than 5% (Figure 2L and M, respectively).
Immunostain for synaptophysin localized to
the background neuropil, but did not stain the
tumor cells. The FFPE tissue from this case
was not found to be optimal for aCGH.
Case Report
Figure 1. Case #1. (A) Densely cellular neoplasm, with hyperchromatic and pleomorphic
astrocytic cells in a well-formed fibrillary background meshwork, with focal necrosis
(H&E stain; 100X magnification). (B) Densely cellular infiltrating portion of the neo-
plasm, with markedly hyperchromatic and pleomorphic overlapping astrocytic cells in a
rather sparse fibrillary background with focal necrosis, including small cells focally
resembling a primitive neuroectodermal tumor but with microvascular proliferation
(H&E stain; 200X). (C) The tumor shows diffuse glial fibrillary acidic protein (GFAP)
positivity with dense fibrillary network in portions (GFAP stain; 400X). (D) The tumor
shows a high Ki67 (MIB1) immunohistochemical nuclear labeling index of up to about
30% (Ki67 stain; 200X). (E) The tumor shows a high p53 immunohistochemical nuclear
labeling index of up to about 70% (p53 stain; 200X).
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Discussion
The ISC is the location of only one third of
1% of pediatric CNS tumors.1,3 Of these, high-
grade gliomas such as the two ISC-GBM cases
reported here constitute only about 1-3%, far
outnumbered by the low-grade gliomas and
ependymomas.6 These are rare tumors, and
even with many recent advances in preopera-
tive imaging, micro-neurosurgery and radia-
tion/chemotherapy protocols,13 the overall sur-
vival after multimodality therapy has been
comparable to that in adults.14,15 A review of
cases of pediatric ISC-GBM reported in the last
two decades is summarized in Table 1.
Clinical features
The clinical presentation of any ISC tumor
relates to the region of the spinal cord
involved.3,16 Up to 60% of pediatric ISC astrocyt -
omas can show holocord presentation,17 which
is unusual in adults. The most common symp-
toms in pediatric ISC tumors are pain (42%),
motor regression (36%), gait abnormalities
(27%), torticollis (27%), and progressive
kyphoscoliosis (24%).6 The cases reported
here presented with non-specific neck pain or
lower extremity dysesthesias, which soon
worsened to progressive weakness and gait
difficulties. In a recent study, preoperative
symptom duration of more than 180 days was
associated with improved survival in infiltra-
tive spinal cord astrocytomas.4
Radiological features
Most cases of ISC-GBM showed MRI imag-
ing characteristics similar to intracranial
GBM. Occasional atypical features included an
Case Report
Table 1. Main clinicopathologic data in the reported pediatric cases of histopathologically confirmed intramedullary glioblastomas of
the spinal cord.
Case Ref. Age/sex Site Surgery RT CTX Rec F/U (months) Outcome
1 31 4 M Holocord Partial None + + 37 DOT
2 31 13 F Cervical Total + + + (CSF) 15 DOD
3 31 15 M Cervical Partial - + + (CSF) 8 DOT
4 20 16 F T12-L1 Subtotal + NA + (CSF) 6 DOD
5 20 14 M T12-L1 Subtotal + ? + (CSF) 4 DOD
6 7 <3 NA Subtotal + + + 23 Alive
7 38 12 C1-C7 Partial NA NA NA NA Alive
8 39 20 M T12-L1 Subtotal + - + (CSF) 11 DOD
9 3 1.8 F C7-T7 Total 55 Gy - + 14 DOD
10 3 1.4 M C7-T2 Subtotal 38 Gy + + 13 DOD
11 3 1.0 M C3-T7 Biopsy 48 Gy + + 24 DOD
12 13 0.7 M C5-L1 Total 40 Gy NA - 144 Alive
13 13 17.9 M T9-L1 Subtotal None NA - 3 DOD
14 16 19 F NA NA NA NA NA 9 DOD
15 16 18 F C7-T7 Total + NA NA 21 DOD
16 16 3 M T7 Biopsy + + + (CSF) 13 DOD
17 16 14 M C2-C7 Subtotal + + NA 9 DOD
18 16 19 M C4-C6 Subtotal + NA NA 12 DOD
19 17 14 M T12-L1 Total NA NA + (CSF) 9 NA
20 5 12 M T11-L1 Subtotal CSI 48.6 NA + (CSF) 7 NA
21 5 9 F T11-L2 Subtotal Focal 38 NA + (CSF) 1 NA
22 5 23 F C3-5 Total Focal 50.4 NA Local 24 NA
23 5 11 F C1-T1 Total Focal 50 NA - 150 Stable
24 5 5 F C3-T2 Biopsy CSI 38, Focal 48 NA - 239 Stable
25 5 10 M C1-2,T6-8 Subtotal CSI 48.4, focal 66 NA + (CSF) 2 NA
26 5 10 M C2-T6 Subtotal Focal 54 NA Local 72 NA
27 5 11 F C2-C7 Subtotal Focal 54 NA + (CSF) 1 NA
28 5 18 F C7-T7 Total Focal 55 NA Local 10 NA
29 5 14 M C7-T2 Subtotal CSI 38.5 NA Local 4 NA
30 5 10 F C3-T7 Biopsy Focal 48 NA + (CSF) 14 NA
31 5 17 M C1-5 Subtotal Focal 54 NA Local 4 NA
32 5 13 F C1-T1 Biopsy Focal 54 NA + (CSF) 1 NA
33 5 3 M C3-T8 Subtotal CSI 34.2, focal 55.2 NA - 88 stable
34 5 15 F T10-11 Subtotal CSI 39.6, focal 51.3 NA + (CSF) 1 NA
35 5 12 M T12 Subtotal Focal 54 NA + (CSF) 4 NA
37 5 9 F T2-7 Subtotal CSI 36, focal 54 NA - 10 Stable
38 Current 14 F C6-T5 Total + + + 14 DOD
39 Current 8 F C3-T4 Subtotal + + + 14 DOD
RT, radiation therapy; CTX, chemotherapy; Rec, recurrence; M, male; F, female; NA, not available; CSI, craniospinal irradiation; CSF, cerebrospinal fluid; DOT, died of toxicity; DOD, died of disease.
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Case Report
Figure 2. Case #2. (A) T1 weighted sagittal mag-
netic resonance images without contrast show an
intramedullary hypointense mass lesion present
within the central portion of the cervical spinal
cord from C3 to T3 levels, producing expansion.
(B) T1 weighted sagittal MR images with con-
trast show an intramedullary enhancing mass
lesion present within the central portion of the
cervical spinal cord, originating from the region
of the central canal, producing expansion. The
spinal cord measures 13 mm at the greatest AP
diameter. The mass shows rim enhancement with
central cystic changes and is surrounded by nor-
mal-appearing spinal cord. This mass extends
from the level of the obex inferiorly to the T4 ver-
tebral body. The maximum bulk of the mass is
present from C3 to T3 levels. This mass produces
remodeling of the posterior vertebral bodies most
notably at C4 to C7. (C) T2 weighted sagittal
MRI showing an expansile intramedullary mass
lesion present within the cervical spinal cord. (D)
Post-contrast T1 weighted axial MRI showing an
enhancing expansile intramedullary mass lesion
present within the central portion of the spinal
cord. (E) Post-contrast T1 weighted axial MRI
showing a ring-enhancing expansile intrame -
dullary mass lesion present within the central
portion of the spinal cord. (F) Moderate to focal
densely cellular neoplasm with moderately
hyperchromatic and pleomorphic loosely
arranged astrocytic cells, with focal marked
microvascular proliferation (H&E stain; 200X).
(G) Areas of necrosis within the astrocytic neo-
plasm. No pseudopalisading is appreciated
(H&E stain; 100X). (H) Moderate to focal dense-
ly cellular neoplasm with moderately hyperchro-
matic and pleomorphic astrocytic cells, with
more than one mitosis in one high-power field,
and with focal moderate microvascular prolifera-
tion (H&E stain; 400X). (J) Moderately hyper-
chromatic and pleomorphic astrocytic cells, with
more than one mitosis in one high-power field
(H&E stain; 400X). (K) Irregular infiltration of
diffusely immunopositive neoplastic astrocytic
cells, with negative images of hyperplastic vessels
(GFAP stain; 100X). (L) The tumor shows a high
Ki67 (MIB1) immunohistochemical nuclear
labeling index of up to about 20% (Ki67 stain;
200X). (M) The tumor shows a negligible p53
immunohistochemical nuclear labeling index of
less than 5% (p53 stain; 200X).
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expansive ISC mass, with signal intensity com-
patible with either low-grade astrocytoma or
ependymoma on T1 weighted images.17 Others
were exophytic with features suggesting
meningioma.16 Both current cases showed
enhancing ISC masses on MRI that were wor-
risome for high-grade glioma.
Surgical resection
In low-grade non-infiltrative tumors such as
ependymomas or pilocytic astrocytomas, radi-
cal excision using recent microsurgical
advances1 before the onset of significant dis-
ability is the standard of care and often results
in improved risk-benefit ratio, and a good long-
term prognosis.18 However, in high-grade
tumors, the value of surgery is less clear. In
pediatric intracranial malignant astrocytomas,
significant improvement in progression-free
survival (PFS) has been reported following
radical tumor resection.19 The data in pediatric
ISC tumors are debatable. In some studies,
gross total or subtotal resection could be
achieved in a majority of patients with mini-
mal short-term morbidity.3,5,7 Radio-cordectomy
and cordotomy was also associated with
improved survival.8 However, radical tumor
resection of high-grade spinal cord gliomas
has not been shown to alter the relentless clin-
ical deterioration and short overall survival of
this devastating tumor, and instead carries the
risk of permanent neurological sequelae and
impairment of the quality of the patients’ brief
remaining lives.4,20 The current recommenda-
tion in high-grade ISC tumors is diagnostic
biopsy followed by postoperative radiation
therapy,3,4 and to reserve extensive surgery for
anaplastic astrocytomas5 and palliation in
patients in whom RT is not well-tolerated or
contraindicated.3,4 The rationale behind radical
surgery in select cases of high-grade spinal
cord gliomas includes obtaining adequate tis-
sue for diagnosis, cytoreductive tumor debulk-
ing, and helping relieve pain.20 In our study,
although both patients had a similar poor out-
come, the histological diversity, with a small
cell component resembling PNET in case #1,
lack of overt high-grade cytology on frozen sec-
tions in case #2, and the resulting need to
establish correct diagnosis along with debulk-
ing justify maximal safe resection.
Pathological features
Histological type and grade are the most
important prognostic factors in ISC glioma.4,5,16
The histopathological features of ISC-GBM are
identical to intracranial tumors in adults,15
except for possibly increased leptomeningeal
involvement owing to proximity to the sub-
arachnoid space.5,6 The current cases showed a
wide histological spectrum ranging from
PNET-like areas in case #1 to relatively bland
areas in case #2. The predictive value of MIB-1
labeling index is unclear,14,16 with no statistical-
ly significant difference in outcome between
cases with MIB-1 labeling index above and
below 5%.16 In our report, both cases were asso-
ciated with high Ki67 labeling indices.
Pediatric high-grade gliomas in children over
three years of age have been found to have a
higher frequency of TP53 mutations and over-
expression (40%),21 indicating potential exist -
ence of two different molecular pathways of
tumorigenesis.21,22 The relationship of p53
overexpression to progression to GBM,14,23
worse progression-free survival,24 and brain
metastases in spinal GBM15 found in some
studies, were not reproduced in other studies.16
In our two cases, p53 immunohistochemical
labeling indices were different (70% in case #1
vs. 5% in case #2), yet they had similar overall
survival of 14 months.
Adult GBM shows a characteristic range of
cytogenetic abnormalities that occur at high
frequency in subsets of tumors. Loss of
chromo some 10, deletion of the p16 gene in
9p21 (often homozygous) amplification of the
EGFR locus, and gain of chromosome 7 are
among the most common events25 seen in
these tumors. None of these cytogenetic
abnormalities, or any others less frequent but
typical of adult GBM, were seen in case #1
described in this report. Our findings correlate
with pediatric glioblastomas in general11 and
are similar to other recent reports on pediatric
GBM.26 Although losses involving 8p, 16p, and
16q are reported occasionally in adult GBM,
they are not frequent in pediatric GBM. Losses
involving the long arm of chromosome 19 are
also infrequent and more typically found in
anaplastic oligodendroglioma.27 In fact, losses
involving 8p and 16q are far more typical of
medulloblastomas.28 From a genetic stand-
point, therefore, the pediatric GBM described
here is more typical of pediatric brain tumors
than adult GBM.
Radiation therapy
Radiation therapy (RT) provides temporary
clinical and radiographic improvement, and
prolongs survival in high-grade gliomas for
some pediatric patients, yet it is rarely cura-
tive.29 An exception is infants and children
under three years of age in whom adjuvant
treatments are reserved for tumor recur-
rence.7,29 The risk of post-radiation growth sup-
pression or second malignancy following treat-
ment of non-infiltrative spinal cord tumors
such as ependymomas or pilocytic astro -
cytomas is not an issue in high-grade gliomas
owing to their short life span. In current treat-
ment protocols, adult patients with high-grade
gliomas receive 5,400-6,000 cGy local radiation
to the brain tumor bed, with a peri-tumoral
margin to account for tumor infiltration, in
daily fractions of 180-200 cGy.8 The spinal cord
is less tolerant of radiation, so the radiation
dose was restricted to 5040 cGy in both our
patients, to avoid the risk of transverse
myelitis. As RT is now considered to be the
standard management in infiltrative high-
grade ISC astrocytomas,4 and many such
patients present with near paraplegia, higher
doses up to 5940 cGy have been reported in the
literature. However, when used in conjunction
with chemotherapy or potential radiosensitizer
(TMZ), a lower dose of radiotherapy is reason-
able. In a recent study, patients with infiltra-
tive spinal cord astrocytomas who received
postoperative RT to a dose of >3500 cGy had a
significantly better survival than those with a
lesser dose or no RT.4 Considering the wide
range of radiation dose reported (Table 1), the
dose is best individualized. 
Chemotherapy
There is no proven effective chemotherapy
for high-grade gliomas in children. Yet, most
children with high-grade gliomas receive
chemotherapy in addition to surgery and radi-
ation therapy.29,30 There are reports of improved
survival in pediatric high-grade ISC tumors by
addition of chemotherapy.31,32 The optimal tim-
ing of chemotherapy and radiation (preopera-
tive vs. postoperative) is debated. While preop-
erative chemotherapy is considered to provide
optimum treatment to undisturbed tumor
microvasculature,3,33 postoperative chemother-
apy may be more efficacious owing to disrup-
tion in the blood-brain barrier.30 Drugs that
have been used in clinical trials in the
Children’s Oncology Group studies include
temozolamide, anti-angiogenesis agents,
immunotoxins, and other maturational and
differentiating agents. In this report, both
patients presented with a rapid decline in
function, necessitating urgent surgical inter-
vention prior to other modalities.
Outcomes 
Patients with infiltrative astrocytoma of the
spinal cord had uniformly poor survival4,19
regardless of age.4 Cases with ISC-GBM invari-
ably progress despite aggressive chemotherapy
and radiation therapy,4,5,8,20 and long-term func-
tional outcomes have been poor.1,4,5,34,35 For pedi-
atric intracranial malignant gliomas, the me -
dian survival with conventional-dose
chemotherapy and radiation therapy is 11-24
months, with an overall survival of 5-20% at
five years,15,32 with a worse outcome for GBM
than grade III gliomas.30,36 Yet, most publica-
tions have not shown a survival advantage in
pediatric intramedullary high-grade gliomas
with multimodality therapy,16,37 owing to high
histological grade, lack of adequate cleavage
plane between tumor and spinal tissue, and
easy access to CSF.7,20
Median overall survival has been reported to
be shorter with neuraxis dissemination than
local failure alone.5 The reportedly higher
lepto meningeal involvement in spinal GBM
Case Report
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(39%) compared to cerebral GBM (27%) indi-
cates CSF spread as a more important cause of
death than direct brainstem involvement,
thereby necessitating regular MRI and CSF
cytology.6,15 In our cases, preoperative CSF
cytology did not show neoplastic cells. The
patients died from complications of respiratory
failure, likely a result of MRI-detected local
tumor recurrence and brainstem involvement.
Conclusions
The spinal cord is a rare site of pediatric
GBM, which has a poor overall survival despite
multimodality therapy. The novel aspects of the
study include diverse histological spectrum,
treatment with Children’s Oncology Group pro-
tocol ACNS0126, and relatively unique CGH
findings, which correlate with pediatric GBM
in general.11 Diagnostic biopsy followed by
radiation with/without chemotherapy is the
standard of care, with the option of radical sur-
gery considered based on judicious assess-
ment of risk-benefit ratio. The finding of rela-
tively unique genotypic abnormalities resem-
bling pediatric embryonal tumors in one of the
cases presented here highlights the potential
value of genome-wide profiling in the develop-
ment of effective treatment strategies.
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